key: cord-0067004-oeunk2ee
authors: Séguier, Denis; Puech, Philippe; Kool, Ronald; Dernis, Léa; Gabert, Héléna; Kassouf, Wassim; Villers, Arnauld; Marcq, Gautier
title: Multiparametric magnetic resonance imaging for bladder cancer: a comprehensive systematic review of the Vesical Imaging-Reporting and Data System (VI-RADS) performance and potential clinical applications
date: 2021-08-25
journal: Ther Adv Urol
DOI: 10.1177/17562872211039583
sha: 53bd28493fdc6e6d6a2453a806910c690999f8a3
doc_id: 67004
cord_uid: oeunk2ee

BACKGROUND: The Vesical Imaging-Reporting and Data System (VI-RADS) score is a novel standardized approach to image and report bladder cancer (BC) with multiparametric MRI (mpMRI). OBJECTIVES: To describe and evaluate the performance of the VI-RADS score using mpMRI and assess its potential clinical applications and limitations. METHODS: A systematic review was conducted using the MEDLINE and EMBASE electronic bibliographic databases between June 2020 and December 2020. All reports deemed relevant to describe the VI-RADS score and assess its performance and applications were retrieved. Results presentation stands as narrative, purely descriptive synthesis based on aggregate studies data. RESULTS: A total of 20 relevant studies were retrieved: three meta-analyses, five prospective studies, and twelve retrospective studies. The retrospective studies covered 1676 patients, while the prospective studies included a total number of 468 patients. Pooled sensitivity, specificity to differentiate muscle-invasive from non-muscle-invasive bladder cancer, ranged from 74.1% to 97.3%, and 77% to 100%, respectively. The chosen VI-RADS score thresholds for this discrimination varied across studies. The interreader agreement ranged from 0.73 to 0.95. Currently, the potential clinical applications of VI-RADS consist of initial BC risk stratification, assessment of neoadjuvant therapies response, and bladder sparing approaches, although further validation is required. CONCLUSIONS: The VI-RADS score helps to discriminate muscle invasive from non-muscle invasive BC with good performance and reproducibility. A simple algorithm based on four basic questions may enhance its popularization. Further studies are required to validate the clinical applications.

Bladder cancer (BC) represents a real public health challenge. About 550,00 bladder cancer cases were diagnosed in 2018, worldwide. 1 One of the main challenges in bladder cancer management lies in the need to quickly distinguish between patients with non-muscle invasive BC (NMIBC) and patients with muscle invasive BC (MIBC). In Europe, the 5-year age-standardized relative survival rate of all BC was approximately 70%, ranging on average from 60% to 80% between countries. 2 Current imaging modalities such as ultrasound or computerized tomography urogram (CTU) have shown limited performance to assess muscle invasion. Despite this, the good overall sensitivity (about 90%) to diagnose BC with CT urography, NMIBC/MIBC discrimination remains challenging. [3] [4] [5] Therefore, the use of complementary investigations, especially with transurethral resection of bladder tumors (TURBT) is needed. To achieve such a goal, other imaging modalities should be further investigated. Magnetic resonance imaging (MRI) was largely investigated in many cancers but not BC. The Prostate Imaging-Reporting And Data System (PI-RADS) and Breast Imaging-Reporting And Data System (BI-RADS) are already validated and broadly used. 6, 7 As of mid-2019, they have been 19 ' reporting and data system' reported. Four of them included the use of MRI (Liver Imaging and Reporting and Data System, Neck Imaging and Reporting and Data System, BI-RADS, and PI-RADS). Panebianco et al. 8 in 2018 provided a novel standardized approach to the imaging and reporting of BC with multiparametric MRI (mpMRI). They developed a Vesical Imaging-Reporting and Data System (VI-RADS) score. After performing a non-systematic literature review in BC and MRI imaging, they proposed the use of T2-weighted (T2W) images, diffusion-weighted magnetic resonance imaging (DWI), dynamic contrast-enhanced image (DCE) tumors appearances to constitute the VI-RADS score. This new score was designed for untreated bladders and does not yet have validated clinical applications. This may explain a relatively low uptake among the radiology and urology communities so far.

Our aims were first to conduct a systematic review of the literature to describe, outreach, and evaluate the performance of the VI-RADS score and secondly to report its potential applications, future outlooks, and limitations.

Between June 2020 and December 2020, we conducted a systematic review using the MEDLINE and EMBASE electronic bibliographic databases. An overall PICO assessment for the review was performed (Supplemental Table 1 ). 9 The search strategy included a mix of the following terms: 'Magnetic Resonance Imaging', 'VI-RADS', 'Non-muscle invasive bladder cancer', 'muscle invasive bladder cancer', 'urinary bladder/neoplasm', 'urinary bladder/diagnosis', and 'urinary bladder/imaging'. The search strategy followed the PRISMA guidelines. 10 Only studies written in English or French were accepted. Studies published between January 2018 and December 2020 were sought. The searches were re-run just before the final submission and one additional study was retrieved for inclusion. We included all reports to assess the VI-RADS score, its performance, and its applications. All selected abstracts were implemented in RAYYAN. 11 Two authors (DS and GM) independently identified studies that potentially met the inclusion criteria using titles and/or abstracts, followed by a full text analysis also performed independently. The full text of these potentially eligible studies was retrieved and independently assessed. No disagreements between the readers were noted. A total of 20 relevant studies: three meta-analyses, five prospective studies, and twelve retrospective studies were retrieved ( Figure 1 ). Extracted information included: study type, population studied, definition of the VI-RADS score, how performance was assessed, control for accuracy of the scoring system, interobserver agreement, sensitivity, specificity, and accuracy for each score. The specificity and sensitivity we reported for each threshold evaluated regarded the likelihood of muscle invasive disease. A risk bias assessment was performed following the Cochrane Handbook for systematic review (Supplemental Table 2 ). 8, 12 Aggregate studies data was used and a purely descriptive narrative synthesis was planned.

Panebianco et al. 8 in 2018 provided a standardized approach to imaging and reporting mpMRI for bladder cancer; as a result, they developed the VI-RADS score. This score was designed to assess the likelihood of muscle invasion on pathology (<pT2 versus ⩾pT2) and is based on a highresolution T2 weighted image (T2WI) acquisition and two functional MRI techniques: diffusionweighted imaging (DWI) and dynamic contrast enhanced (DCE). These sequences were chosen for the combined advantages they provided; T2W allowed the assessment of the detrusor, while DWI allowed the muscularis propria assessment and the DCE sequence provided accurate information concerning the inner layer. After staging the normal and pathological aspect of each bladder wall layers in each MRI sequences, they offered a five-stage score ranging from 1 (highly unlikely muscle invasion) to 5 (invasion of muscle and beyond the bladder is very likely). Stage 3 corresponds to an equivocal aspect of muscular invasion. It should be noted that spin-Echo T2 weighted image (T1W) acquisition is also required to diagnose eventual hemorrhage and blood clots in the bladder and bone metastasis; however, its findings do not contribute to the score.

As stated in the original VI-RADS publication, 8 antispasmodic agents should be administered to the patient, priory to image acquisition, to minimize artifacts resulting from bowel peristalsis. The authors advised that one apply saturation bands on the anterior abdominal wall to reduce respiratory influences. They also stressed the major importance of adequate distension of the bladder. As a result, patients are instructed to void 1-2 hours before imaging and to drink 500-1000 ml of water 30 minutes before the examination. MRI can be used as a real-time imaging technique to determine bladder filling. They stated the optimal bladder volume for imaging is around 300 ml. In case of under distended bladder, the examination should be delayed by 30-60 minutes. For patients with a urethral catheter, 250-400 ml of sterile saline can be instilled to distend the bladder.

With regards to T2WI acquisition, three planar (axial, coronal, sagittal) images without fat suppression are required. This sequence is the first that radiologists will be looking at. To gain appropriate spatial resolution, 2D or 3D, fastspin-echo (FSE) or turbo-spin-echo sequences are acquired with a slice thickness of 3-4 mm and a small field of view (FOV). 3D sequences can also be used, with thinner slices and the ability to reconstruct images in the 3 planes.

DWI acquisition is a type of functional acquisition and based on the study of Brownian movements of water molecules. It is possible to carry out acquisitions in DWI sequences on the coronal and/or sagittal planes, particularly for lesions at the bladder dome. The DW sequences have multiple b-values, typically 800-1000 s/mm 2 b-values. Contrary to prostate MRI, care must be taken not to produce a too high b-value, as it could harm the signal-to-noise ratio. 13 The resolution of the DWI sequence, especially in its anatomical interpretation, is limited due to the signal suppression of the background, making confrontation with T2W images therefore essential.

Dynamic, contrast-enhanced MRI provides accurate information concerning the inner layer of the bladder wall and tumor enhancement. A gadolinium-based contrast agent is administered using a power-injector system at a dose of 0.1 mmol/kg of body weight at a rate of 1.5-2.0 ml/s; it is followed by a saline flush.

Each acquisition sequence generates a result for a bladder lesion that will be ranked from one to five, in three categories. T2WI acquisition allows for the analysis of the structural category (SC), while DWI and ADC map are the support of the DW category (DW) and DCE is the support of the contrast-enhanced category (CE).

Firstly, T2WI images are analyzed to evaluate the integrity of the muscularis propria (detrusor) and proceed with the structural category (SC) ranging. Figure 2 ). The combination of these questions may ease mpMRI scoring and control. To illustrate this simple VI-RADS scoring technique, we provide 2 examples of mpMRI, with their corresponding VI-RADS scores ( Figure 3 ). This algorithm serves as a surrogate to simplify the scoring method for clinicians. This algorithm is not meant to replace a thorough radiological examination. In addition, since tumor location drives unequal likelihood of muscle invasion, 14 a systematic use of bladder diagrams is recommended. Such diagram also enhanced the way mpMRI is reported, enhancing communication between radiologists and urologists.

Retrospective studies From our review, 12 retrospective studies performed between 2019 and 2020 were retrieved (Table 1) . 15 Step by step method for VI-RADS scoring system.

Adapted with permission from Panebianco et al. 8 VI-RADS, vesical imaging-reporting and data systems.

from NMIBC. For a VI-RADS 2 threshold, the estimated sensitivity was 100% and the specificity ranged from 21% to 81% (based on 3 studies including 61 patients). 21, 22, 26 For a VI-RADS 3 threshold, all 12 studies provided data. The sensitivity ranged from 78% to 100%, specificity from 44% to 100%. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] For a VI-RADS 4 threshold, sensitivity ranged from 63 to 100%, specificity from 76% to 96% (including 7 studies with 88 patients). 15, 16, 19, [21] [22] [23] Finally, for a VI-RADS 5 threshold, the sensitivity ranged from 68% to 86%, and the specificity from 95% to 99%. 15, 17, [20] [21] [22] [23] 26 As outlined here, the number of patients used to assess the VI-RADS score performance for each given threshold is limited. There is an unmet need for larger studies.

The estimated area under the curve (AUC) in these studies, the proposed results ranged from 0.83 (in a specified estimated AUC for a T2WI acquisition) to 0.97 (a pooled AUC on every 8 journals.sagepub.com/home/tau threshold, according to Vaz and Zaparolli 22 ) . When available, the overall interreader agreement was rated from fair to excellent, across studies based on the Kappa score ranging widely from 0.43 to 0.92. In the majority of the studies, a dedicated reader, specialized in uro-radiology, conducted the scoring. Only one study included a urologist as a reader. 24 Prospective studies. From our systematic review, five prospective studies were retrieved. [27] [28] [29] [30] [31] These studies included a total number of 799 patients. Del Guidice et al. 28, 30 studies included a total of 380 patients, Metwally et al. 31 included 331 patients; while the two other studies included 50 and 38 patients respectively. 27, 29 Three studies used a VI-RADS 3 threshold. 27, 28, 31 The reported sensitivity was similar to retrospective studies and ranged from 78% to 92%, while the specificity ranged from 88% to 91%. Only Marchioni et al. 29 have specifically chosen a VI-RADS 4 threshold to discriminate NMIBC from MIBC. Their sensitivity was estimated at 85.7% and their specificity 86.9%; however, only 7 patients were classified at this score level (for a total of 38 patients included in the study and 68 tumors evaluated).

The latest report from Del Guidice et al. 30 included 149 patients, also using the VI-RADS 4 threshold for NMIBC/MIBC discrimination, although the primary endpoint of this study was to assess the likelihood of locally advanced disease in the pre-TURBT setting. For this endpoint, they chose a VIRADS 5 threshold, which resulted in an estimated sensitivity of 90.2% and a specificity of 98.1%.

These prospective studies reinforced an overall good-to-excellent interreader agreement, with a Kappa score ranging from 0.87 to 0.92 and demonstrating a high AUC ranging from 0.83 to 0.94.

Meta-analysis. Two meta-analyses provided an overall synthesis of VI-RADS performance based on the studies aforementioned. 32, 33 Woo et al. 32, 34 included a total number of 1170 of patients from six different studies, with an overall sensitivity of 83% and a specificity of 90%. It should be noted that this meta-analysis pooled different thresholds for the NMIBC/MIBC discrimination, therefore limiting data extrapolation. They reported an AUC of 0.94 and a good-to-excellent overall interreader agreement, ranging from 0.81 to 0.92 (Kappa score). They also reported significant heterogeneity between the studies based on the Cochran's Q test (Q = 29, p < 0.01) and considerable heterogeneity based on the Higgins I2 statistics (I2 for sensitivity = 88% and I2 for specificity = 91%).

Luo et al. 33 included a total of 1064 patients from six different studies (5 studies were included in the previously described meta-analysis). They calculated with pooled data an overall sensitivity of 90% and a specificity of 86%, with the same limitations previously explained. They also reported an AUC of 0.93. Using VI-RADS 4 as the cutoff value, a 77% sensitivity, 97% sensibility, and an AUC of 0.92 were reported. They stressed that the meta-regression analysis revealed that the study design (p = 0.01) and the surgical pattern of reference standard (p = 0.02) were a source of significant heterogeneity of the pooled sensitivity. The interreader agreement was not assessed in this study.

One additional meta-analysis from Del Guidice et al. 35 focused on the specifically of the estimation of inter-reader agreement. They selected 8 studies, for a total of 1016 patients, analyzed by 21 uro-radiologists. They were able to confirm an excellent inter-reader agreement of the VI-RADS score to discriminate MIBCs from NMIBCs. The pooled weighted mean kappa estimate was 0.83 [95% confidence interval (CI): 0.78-0.88].

As outlined in this manuscript, MRI and the VI-RADS score are promising. In fact, as of January 2021, 23 ongoing clinical trials are evaluating the role of MRI in all stages of bladder cancer (Table 2 ). These trials aim to either evaluate mpMRI and the VI-RADS score or each one separately, in all BC stages and to establish the global interest of this imaging modality. Results are eagerly awaited.

Interestingly, the ability of urologists to discriminate stage and grade using only cystoscopy findings is relatively good. A prospective trial, including 224 patients, reported that the positive predictive values for predicting low-and highgrade cancers through cystoscopy were 85.8% landmark SWOG 8710 trial. 38 In this trial, patients were randomized between RC alone or NAC plus RC, and complete response (ypT0) was reported in 38% of the patients in the NAC arm, versus 15% for patients undergoing RC alone. This notion raised the question of potential bladder sparing therapies for this subset of patients.

A recent retrospective study, from a prospectively-maintained single institution database, investigated the reliability of staging post NAC. 39 In this study, 114 patients underwent TURBT after NAC and prior to RC. They showed that post-NAC TURBT failed to reliably predict ypT stage at RC since up to 32% of patients were falsely downstaged to NMIBC on post-NAC TURBT. In fact, 53 patients had no evidence of disease (rT0) on post-NAC TUR; however, of these, only 25 (47%) were ultimately ypT0 on final RC pathology. The remaining 28 (53%) had residual disease at RC, including 13 (25%) with residual CIS and 12 (23%) with residual ⩾ypT2 disease, highlighting the challenges in accuratelypredicting tumor stage after NAC without definitive RC. This is an area where mpMRI, in addition to TURBT, might improve outcomes by better selecting patients to bladder sparing therapies. This field of research is highly relevant, since multiple trials are currently investigating the ability of bladder sparing approaches post NAC for MIBC, notably RETAIN (Clinicaltrial.gov identifier: NCT02710734), A031701 (Clinicaltrial. gov identifier: NCT03609216), and Hoosier (Clinicaltrial.gov identifier: NCT03558087) trials. However, care needs to be taken when staging with MRI post NAC as well due to inflammatory infiltrations and/or fibrous changes caused by the chemotherapy that can make precise staging more challenging. 40 Regarding this question, a useful insight was provided by a study of Ngyuen et al. 41 in 2017. They studied 20 patients with pT2 bladder cancer who underwent NAC. Fifteen patients were defined as responders. They demonstrated that a high level of ADC heterogeneity is associated with tumor resistance. Compared to responders, resistant cases had significantly higher entropy (p < 0.01) and lower uniformity (the criteria assessing the image homogeneity) (p = 0.01).

More recently, Ahmed et al. 42 evaluated in a prospective study including 90 patients the diagnostic performance of DCE MRI and DWI in assessing pathologic complete response (pCR) after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. They specially analyzed the correlation between pCR and semiquantitative parameters (wash-in rate, wash-out rate) and ADC value. They reported confirmation of 43.3% pCR on cystectomy specimens.

Regarding imaging analysis, they demonstrated that pCR had negative correlation with the washout rate (r = −0.701, p = 0.01), ADC value (r = −0.621, p = 0.01) and had no significant correlation with wash-in rate (r = 0.187, p = 0.14). They concluded that the semi-quantitative parameter (wash-out) derived from DCE MRI and ADC could assess the tumor's complete pathologic response. They reported the potential of those parameters in assessing tumor response to NAC in MIBC for the combination of washout rate and ADC value. Despite this, like other authors, they also report the difficulty induced by the lack of standardization of ADC measurement technique, representing an inherent limitation of DWI.

The performance of MRI to assess tumor response to neoadjuvant pembrolizumab in MIBC was also recently reported in an ancillary study of PURE-01 (open-label, single-arm, phase II study assessing the activity of pembrolizumab as neoadjuvant therapy before RC in patients with MIBC). 43, 44 In PURE-01, 143 T2-T4aN0M0 patients received 200 mg pembrolizumab intravenously for three cycles before radical cystectomy. The reported pCR was 42%. Out of the 143 included patients, 136 patients underwent pre-and post-pembrolizumab mpMRI. 45, 46 Nine patients received additional neoadjuvant chemotherapy; four could not receive intravenous gadolinium contrast due to severe renal function impairment. This ancillary study's objective was to evaluate the association between bladder mpMRI findings and the complete pathological response (pT0). In their first publication, they reported that mpMRI rightfully diagnosed a pT0 stage in 23/37 (62%) and 19/26 (73%) patients in internal and external review, respectively. 45 These assessments were only qualitative; in the first exploratory analysis, the mean ADC values in post-therapy regions of interest was not associate with pathological findings. In the second publication specifically focused on this question, they reported an overall estimated accuracy of 0.72 in predicting ypT0N0 response for mpMRI. In addition, they evaluated the performance of each MRI sequences alone and the performance of biparametric MRI. The prediction of pathologic-downstaging to non-muscle-invasive 12 journals.sagepub.com/home/tau cancer was accurate in 95% of patients in either assessment method. 46 As a result, those publications paved the way to support mpMRI as a non-invasive tool in the neoadjuvant setting; despite this, to our knowledge, the previously mentioned study did not use the VI-RADS score.

Bladder sparing approaches MRI and the VI-RADS score may also play a role in MIBC trimodal therapy (TMT), one of the most promising bladder-sparing approaches. In fact, the largest retrospective single center cohort so far, with a median follow-up of 7 years, reported comparable oncological outcomes to RC: the 5and 10-yr overall survival rates were 57% and 39%, respectively. 47 The rate of salvage cystectomy at 5 years was 29%. MRI and VI-RADS score may help to improve patient selection to TMT since the overall MRI performance to discriminate T2 tumors from T3-4 seems promising. Daneshmand et al. 48 evaluated the accuracy of mpMRI to detect extravesical BC and lymph node-positive disease in patients with MIBC in a prospective study. They included a total number of 122 patients with 15 patients (12.3%) pT4, 27 (22.1%) pT3, and 38 (31.1%) pT2. They found that mpMRI (with DCE) correctly differentiated organ-confined MIBC (pT2 pN0) from locally advanced (pT3-4 pN0) MIBC in 74% of lymph node-negative cases. The overall sensitivity and specificity for such differentiation were 87.5% and 47.6% respectively, with an accuracy to detect lymph node positive disease was 80% (40% sensitivity and 91% specificity).

Moreover, enhancing post radiation-based bladder sparing staging is of paramount importance. In fact, a recent single-center retrospective study on patients with MIBC (cT2-4aN0-2M0) treated with curative intent RT assessed the role of tumor bed biopsy. 49 Although the large majority of patients were correctly staged with cystoscopy, the authors reported a 5% rate of residual MIBC in optically normal bladders post TMT. In fact, Yoshida et al. 50 in 2010 included in a small prospective study (n = 20) T2-4aN0M0 MIBC patients who underwent induction 'low-dose' chemoradiotherapy (40 Gy with concomitant 2 cycles of cisplatin) followed by partial (n = 13) or radical cystectomy (n = 7). They reported that all macroscopic residual tumors were depicted with the use of mpMRI. The use of DWI alone was associated with a high sensitivity of 92% (12 of 13 patients concerned) to predict pathologic residual BC. As a result, a standardized use of DWI, which was not the case at time of this study, may help improve the detection of residual tumor after radiation-based therapies for MIBC.

The ability of mpMRI to determine the tumor aggressiveness was previously explored. Takeuchi et al stated that the presence of a low ADC (<1 × 10 −3 mm 2 /sec) could indicate that the tumor is more likely to be high grade. 13 

Aside of the previously outlined limitations regarding the VI-RADS score and our risk of bias analysis, there are several other shortcomings that should be pointed out. As the VI-RADS developers have recognized, the aim of this system was to create a score for untreated patients to differentiate NMIBC from MIBC. 54 Therefore, the potential clinical applications outside of this scope and outlined in this manuscript should be validated by dedicated studies. Moreover, the current state of the score does not take into account several validated predictors of muscle invasion such as ureteral infiltration (responsible of hydronephrosis) or the number and location of lesions (including diverticular tumors). In addition, there is currently no reliable way to depict several adverse pathological features commonly use in patient risk stratification with the use of mpMRI such as CIS, lymphovascular invasion, and variant histology. Currently, the VI-RADS score should serve as an adjunction of pathological assessment.

Several reports on MRI and VI-RADS score had also offered the possibility of using MRI in NMIBC surveillance. However, such use of mpMRI will require serial acquisitions over time, which is associated with a heavy cost-related burden compared to cystoscopy. 55 In addition, systematic use of mpMRI will require multiple contrast injection that are associated with side effects. 56, 57 Some authors also argued that the cost-reduction induced by the use of the VI-RADS in the staging settings might be beneficial; however, dedicated cost-analysis studies are warranted to address this point. MRI accessibility is another challenge: the use of mpMRI should not delay treatment, especially in MIBC. 58, 59 Several reports have shown the negative effect on survival associated with a delay in radical treatment administration. 60, 61 Moreover, the reliability in scoring among non-specialized radiologists is unknown. The data outlined in this report are mainly from academic centers. Future, larger studies should validate the inter-reader agreement.

The VI-RADS score was designed to assess the likelihood of muscle invasion using mpMRI. This score helps to discriminate MIBC from NMIBC, with good performance and reproducibility in a non-invasive manner. A simple algorithm based on four basic questions may enhance its popularization. Besides initial BC risk stratification, response to post neoadjuvant therapies and bladder sparing approaches are other potential clinical applications of the score. 

The global burden of urinary bladder cancer: an update

Trends in bladder cancer incidence and mortality: success or disappointment?

Recent advances in imaging cancer of the kidney and urinary tract

Role of imaging in the local staging of urothelial carcinoma of the bladder

The role of imaging in bladder cancer diagnosis and staging

BIRADS classification in mammography

PI-RADS prostate imaging -reporting and data system: 2015, version 2

Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting and Data System)

Chapter 9: summarizing study characteristics and preparing for synthesis

Preferred reporting items for systematic review and metaanalysis protocols (PRISMA-P) 2015 statement

Rayyan-a web and mobile app for systematic reviews

Chapter 25: assessing risk of bias in a non-randomized study

Urinary bladder cancer: diffusion-weighted MR imaging-accuracy for diagnosing T stage and estimating histologic grade

Bladder neck urothelial carcinoma: a urinary bladder subsite carcinoma with distinct clinicopathology

Diagnostic accuracy and interobserver agreement for the vesical imaging-reporting and data system for muscle-invasive bladder cancer: a multireader validation study

VI-RADS: multiinstitutional multireader diagnostic accuracy and interobserver agreement study

Multiparametric MRI for bladder cancer: validation of VI-RADS for the detection of detrusor muscle invasion

Evaluation of the value of the VI-RADS scoring system in assessing muscle infiltration by bladder cancer

Validation of vesical imaging reporting and data system for assessing muscle invasion in journals.sagepub.com/home/tau 15 bladder tumor

Multiparametric MRI of the bladder: interobserver agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center

Evaluation of Vesical Imaging-Reporting and Data System (VI-RADS) scoring system in predicting muscle invasion of bladder cancer

Diagnostic accuracy of retrospective application of the vesical imagingreporting and data system: preliminary results

Detection of muscle-invasive bladder cancer on biparametric MRI using Vesical Imaging-Reporting and Data System and Apparent Diffusion Coefficient values (VI-RADS/ADC)

Clinical utility of the vesical imaging-reporting and data system for muscle-invasive bladder cancer between radiologists and urologists based on multiparametric MRI including 3D FSE T2-weighted acquisitions

MP80-03 staging accuracy of Vesical Imaging-Reporting and Data System (VI-RADS) for bladder cancer

Vesical imagingreporting and data system for multiparametric MRI to predict the presence of muscle invasion for bladder cancer

Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with Vesical Imaging Reporting and Data System (VI-RADS) application

Prospective assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its clinical impact on the management of high-risk non-muscle-invasive bladder cancer patients candidate for repeated transurethral resection

Preoperative detection of VI-RADS (Vesical Imaging-Reporting and Data System) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time-to-cystectomy: time to reconsider the need for primary deep trans-urethral resection of bladder tumor in case of locally advanced disease?

The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study

Diagnostic performance of vesical imaging reporting and data system for the prediction of muscle-invasive bladder cancer: a systematic review and metaanalysis

Use of Vesical Imaging-Reporting and Data System (VI-RADS) for detecting the muscle invasion of bladder cancer: a diagnostic meta-analysis

Corrigendum to 'Diagnostic performance of vesical imaging reporting and data system for the prediction of muscle-invasive bladder cancer: a systematic review and meta-analysis

Systematic review and meta-analysis of Vesical Imaging-Reporting and Data System (VI-RADS) inter-observer reliability: an added value for muscle invasive bladder cancer detection

Predicting grade and stage at cystoscopy in newly presenting bladder cancers-a prospective double-blind clinical study

Replacing TURBT with mpMRI for staging MIBC: pilot data from the BladderPath study

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

Clinical restaging and tumor sequencing are inaccurate indicators of response to Neoadjuvant chemotherapy for muscle-invasive bladder cancer

The effects of neoadjuvant chemotherapy and chemo-radiation therapy on MRI staging in invasive bladder cancer: comparative study based on the pathological examination of whole layer bladder wall

Quantitative assessment of heterogeneity in bladder tumor MRI diffusivity: can response be predicted prior to Neoadjuvant chemotherapy?

Diagnostic performance of contrast-enhanced dynamic and diffusion-weighted MR imaging in the assessment of tumor response to neoadjuvant therapy in muscle-invasive bladder cancer

Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscleinvasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study

Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies

Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: preliminary findings from the PURE-01 study

The value of multiparametric magnetic resonance imaging sequences to assist in the decision making of muscle-invasive bladder cancer

Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscleinvasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience

Preoperative staging of invasive bladder cancer with dynamic gadolinium-enhanced magnetic resonance imaging: results from a prospective study

Refining assessment of response to radiationbased therapy for muscle-invasive bladder cancer: is post-treatment tumor bed biopsy always necessary? Urol Oncol. Epub ahead of print 23

Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscleinvasive bladder cancer

Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness

Application of bi-planar reduced field-of-view DWI (rFOV DWI) in the assessment of muscle-invasiveness of bladder cancer

Prediction of muscle invasion of bladder cancer: a comparison between DKI and conventional DWI

Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's letter to the editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting and Data System)

The economics of bladder cancer: costs and considerations of caring for this disease

Gadolinium deposition in brain: current scientific evidence and future perspectives

Disappearance of T1-weighted MRI hyperintensity in dentate nuclei of individuals with a history of repeat gadolinium administration

Overview of VI-RADS in bladder cancer

VI-RADS scoring criteria for alternative riskadapted strategies in the management of bladder cancer during the COVID-19 pandemic

An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma

Contemporary concepts of radical cystectomy and the treatment of bladder cancer

Visit SAGE journals online journals

The authors declare that there is no conflict of interest.

The authors received no financial support for the research, authorship, and/or publication of this article.